Latest
21:33
【CSPC Pharmaceutical (01093.HK): SYH2062 Hypertension Phase II Trial Initiated at First China Site; CRB-701 FDA Cleared for Pivotal OPSCC Trial】NewTimeSpace News: CSPC Pharmaceutical announced that its siRNA antihypertensive candidate SYH2062 has initiated Phase II trials in China for adult primary hypertension, while its Nectin-4-targeting ADC CRB-701, out-licensed to Corbus, received FDA clearance for the registrational TEMPO-1 trial in second-line oropharyngeal squamous cell carcinoma with enrollment expected in Q3 2026, following two prior Fast Track designations.
Tag:
CSPC PHARMA01093.HK
19:28
19:27
17:22
【PCCW Limited (00008.HK): Confirms Holding Approximately 52.22% of HKT Combined Units】NewTimeSpace News: PCCW disclosed in an announcement dated 29 July that it confirms it currently holds approximately 52.22% of the total issued combined units of HKT Trust and HKT Limited.
Tag:
PCCW Limited00008.HK
17:17